MHRA-100873-PIP01-23

Key Facts

Active Substance
Active Substance:
  • Meningococcal Group A, C, W-135 and Y conjugate vaccine
Invented Name
  • Menveo
  • Menveo
  • Menveo
  • Menveo
  • Menveo
  • Menveo
  • Menveo
  • Menveo
  • Menveo
  • Menveo
  • Menveo
  • Menveo
  • Menveo
  • Menveo
  • Menveo
  • Menveo
  • Menveo
  • Menveo
  • Menveo
  • Menveo
  • Menveo
  • Menveo
  • Menveo
  • Menveo
  • Menveo
  • Menveo
  • Menveo
  • Menveo
  • Menveo
  • Menveo
  • Menveo
  • Menveo
  • Menveo
  • Menveo
  • Menveo
PIP Number MHRA-100873-PIP01-23
Pharmaceutical form(s)
Pharmaceutical form(s):
  • Solution for injection
Therapeutic area
Therapeutic area:
  • Vaccines
Conditions / Indications
Conditions / Indications:
  • Meningococcal meningitis
Route(s) of administration
Route(s) of administration:
  • Intramuscular use
PIP applicant
  • GlaxoSmithKline UK Limited
  • Country United Kingdom
  • Tel 02080475000
  • Email oax52639@gsk.com
Decision Type
Decision Type
W: decision granting a waiver in all age groups for the listed condition(s).
Compliance Check
Compliance Check
No
Compliance Check Decision Date
Compliance Check Procedure Number

Decision Document

Decision Document Decision Document on a Paediatric Investigation Plan (PIP):Meningococcal Group A, C, W-135 and Y conjugate vaccine.pdf
Published Date 19/12/2023